You are here: Home » PTI Stories » National » News
Business Standard

Mylan, Biocon seek to accelerate introduction of adalimumab biosimilar in EU

Press Trust of India  |  New Delhi 

today said it along with has agreed to accelerate introduction of in through Mylan's in-licensing arrangement with Kirin Biologics.

is indicated for patients suffering from various autoimmune diseases.

"and have agreed to accelerate introduction of in through Mylan's in-licensing arrangement with Kirin Biologics (FKB)," said in a statement.

FKB's product is at an advanced stage of review and could potentially obtain approval in in the second half of 2018, it added.

"We believe that through this arrangement, could commercialise FKB's Adalimumab in EU around market formation. Biocon retains its economic interest in this arrangement vis-a-vis Mylan in line with its existing global collaboration with Mylan for monoclonal antibodies," the said.

Shares of Biocon today closed at Rs 613.15 per scrip on BSE, down 0.77 per cent from the previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, April 11 2018. 20:30 IST
RECOMMENDED FOR YOU